BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) will host a call on June 4, 2024, at 8:00 am ET to present results from Month 12 and Month 18 of Cohort 5 in the Phase 2 PROPEL 2 trial. This trial evaluates the efficacy of the investigational oral therapy infigratinib in children with achondroplasia. Dr. Ravi Savarirayan from Murdoch Children’s Research Institute in Melbourne will join the call. The live webcast can be accessed via the 'Events' page in the Investors section of BridgeBio's website, with a replay available for 90 days post-event.

Positive

• Hosting a call to discuss clinical trial results may increase investor transparency and confidence.
• The inclusion of Dr. Ravi Savarirayan, a reputable global lead investigator, adds credibility to the trial results.
• The accessibility of the webcast for 90 days allows prolonged investor engagement.

Negative

• Results are from only one cohort (Cohort 5), which may limit the generalizability of the findings.
• No financial or revenue impact mentioned, leaving potential uncertainty about the commercial viability of infigratinib.
• The PR does not provide specific data or outcomes, making it difficult to assess the effectiveness of infigratinib.

PALO ALTO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along with Ravi Savarirayan, M.D., Ph.D., of Murdoch Children’s Research Institute in Melbourne, Australia, and the global lead investigator for PROPEL 2, will host a call on June 4, 2024, at 8:00 am ET to share results from Month 12 and Month 18 from Cohort 5 of PROPEL 2, a Phase 2 trial of the investigational oral therapy infigratinib in children with achondroplasia.

To access the live webcast, please visit the “Events” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.

BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220

FAQ

When will BridgeBio present the Phase 2 Cohort 5 results of infigratinib?

BridgeBio will present the Phase 2 Cohort 5 results on June 4, 2024, at 8:00 am ET.

How can investors access the live webcast for BridgeBio's Phase 2 trial results?

Investors can access the live webcast via the 'Events' page in the Investors section of BridgeBio's website.

Who is the global lead investigator for PROPEL 2 in BridgeBio’s trial?

Dr. Ravi Savarirayan from Murdoch Children’s Research Institute in Melbourne is the global lead investigator.

What is the focus of BridgeBio’s Phase 2 PROPEL 2 trial?

The Phase 2 PROPEL 2 trial focuses on evaluating the efficacy of the investigational oral therapy infigratinib in children with achondroplasia.

How long will the replay of BridgeBio’s webcast be available?

The replay of BridgeBio’s webcast will be available for 90 days following the event.